Sanofi-aventis receives approvable letter for rimonabant for weight control, non-approvable for smoking

New York, Feb. 17 - Sanofi-aventis said the Food and Drug Administration gave rimonabant an approvable letter for weight management and a non-approvable letter for smoking cessation.

The Paris-based pharmaceutical company said it will "continue to work in close collaboration with the FDA."

Rimonabant is the first in a new class of therapeutic agents called CB(1) blockers, according to Sanofi-aventis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.